Study of KN026 plus chemo for HER2-positive colorectal or bile duct cancer
Part of Cancer, Digestive system clinical trials.
This trial tests a new combination of drugs (KN026 plus chemotherapy, with or without KN-046) for people with HER2-positive colorectal or bile duct cancer that has spread. The goal is to see if this treatment can help shrink or control the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You must have HER2-positive colorectal cancer that has spread and is not removable by surgery, or HER2-positive bile duct or gallbladder cancer.
- For colorectal cancer: You must not have had chemo for the spread, or if you had chemo after surgery, it must have been more than 6 months before the cancer came back.
- Your tumor must have a normal RAS and BRAF gene (this will be checked by a test).
- Your heart must pump at least 50% of normal (this will be checked).
- Your liver, kidney, and blood counts should be within acceptable ranges (your doctor will check).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called JSKN003 against the usual treatments for people with HER2-positive advanced colorectal cancer that has stopped responding to standard chemotherapy. It aims to see if the new drug can help shrink or control the cancer better than current options.
This study tests two new immunotherapy drugs (KN026 and KN046) with or without chemotherapy (XELOX) for people with a specific type of advanced stomach cancer that makes too much HER2 protein. The goal is to see if this combination can shrink tumors or slow the cancer.
This trial tests KN026 together with chemotherapy in people with HER2-positive advanced stomach (or gastro-esophageal junction) cancer that has already grown despite first-line treatment with trastuzumab plus chemotherapy. It may help by targeting HER2 while also using chemotherapy to control the cancer.
This Phase 3 study tests whether taking KN026 with HB1801 as first treatment works better and is safe for people with HER2-positive breast cancer that has come back or spread. It may help by improving tumor response and delaying progression compared with the study’s treatment plan.
This trial tests a combination of three drugs (trastuzumab rezetecan, adebrelimab, and lenvatinib) for people with advanced bile duct or gallbladder cancer that has HER2 protein on its cells. The goal is to see if this combination can help shrink tumors or slow the cancer's growth.
This trial tests a combination of two drugs, KN 046 and regorafenib, in people with a type of advanced colorectal cancer that has not responded to previous treatments. The goal is to see if this combination can help shrink or control the tumor.
Hear when a new HER2-positive Colorectal Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.